Medications to Manage Transfer to Women and Children on AndroGel (testosterone topical): First-Line and Beyond

At a glance

• Incidence: The FDA received post-marketing reports of secondary exposure sufficient to issue a Black Box Warning in 2009; exact incidence is not quantified in controlled trials but cases number in the hundreds in pharmacovigilance databases
• Typical timeline: Virilization signs in children can appear within weeks to months of repeated exposure; clitoral enlargement and pubic hair in girls, penile growth and premature adrenarche in boys
• First-line management: Immediate cessation of exposure plus topical site washing; no pharmacological intervention required if caught early
• Second-line management: Anti-androgen therapy (spironolactone, flutamide, or bicalutamide) for a contact who shows ongoing or significant virilization
• When to escalate: Refer to pediatric endocrinology if a child shows any sign of precocious puberty; refer to adult endocrinology or gynecology if a woman develops androgenic alopecia, clitoral changes, or menstrual disruption
• When to discontinue AndroGel: If behavioral modifications fail to prevent repeated transfer and no alternative TRT formulation is feasible, the prescribing clinician should reassess the route of testosterone delivery

Why Transfer Happens and Why It Matters

AndroGel delivers testosterone through a hydroalcohol gel applied to the shoulders, upper arms, or abdomen. Once the carrier alcohol evaporates, a residue of testosterone remains active on the skin surface for several hours. The AndroGel 1.62% prescribing information states that without washing, significant testosterone can transfer to a partner or child through direct skin contact.

The clinical consequence is virilization, a dose-dependent androgenic effect on tissues that are sensitive to testosterone or its 5-alpha-reduced metabolite dihydrotestosterone (DHT). In premenopausal women, even modest supraphysiologic androgen exposure can disrupt the hypothalamic-pituitary-ovarian axis. In children, the endocrine-disrupting effect is particularly serious because any exogenous androgen can accelerate bone age, trigger premature closure of growth plates, and initiate irreversible secondary sexual characteristics.

The FDA Black Box Warning issued in 2009 specifically calls out virilization in children as a serious risk, citing case reports where children who had contact with an AndroGel user developed penile or clitoral enlargement, premature pubic hair, increased erections, and aggressive behavior.

Step One: Exposure Cessation as the Non-Pharmacological First-Line

Before any medication is considered, complete cessation of further transfer is non-negotiable. The Endocrine Society's clinical practice guidelines on testosterone therapy emphasize that application site coverage with clothing, thorough handwashing with soap and water immediately after application, and avoidance of skin-to-skin contact at the application site for at least six hours are required safety measures.

If a contact has already been exposed, washing the exposed skin area with soap and water within minutes to an hour can meaningfully reduce absorbed dose. Studies of topical drug absorption show that early washing after dermal exposure can remove a substantial fraction of residue before systemic absorption is complete, though efficacy diminishes rapidly beyond 30 minutes.

For the AndroGel user, options that reduce transfer risk while maintaining therapeutic testosterone levels include:

• Switching to testosterone cypionate or enanthate IM injections, which carry zero transfer risk
• Switching to a testosterone pellet implant, which is entirely subcutaneous
• Switching to a testosterone nasal gel (Natesto), which has a minimal skin transfer profile

Pharmacological Management of Virilization in Exposed Women

When a woman has signs of androgen excess from transfer exposure, the goal of pharmacological management is to block androgen action at the receptor level or reduce androgen production, while the source of exogenous testosterone is being addressed.

Spironolactone (First-Line Anti-Androgen in Women)

Spironolactone is a potassium-sparing diuretic with well-characterized anti-androgen properties. It blocks the androgen receptor and inhibits 5-alpha reductase, reducing DHT-mediated effects. It is widely used off-label for androgen-excess conditions including polycystic ovary syndrome (PCOS), hirsutism, and androgenic alopecia.

Dose range: 50 to 200 mg orally per day, typically divided as 50 to 100 mg twice daily. Most clinicians start at 50 mg/day and titrate based on tolerability and response over four to eight weeks.

Monitoring: Serum potassium and blood pressure should be checked at baseline and at four to six weeks. Hyperkalemia is the main serious risk, particularly in women with renal impairment. The FDA label for spironolactone carries a warning for tumor-inducing potential in animal studies, though this has not translated to clear clinical risk in humans at standard doses.

Interactions to watch: Combining spironolactone with ACE inhibitors, ARBs, or potassium supplements significantly increases hyperkalemia risk. NSAIDs can blunt spironolactone's diuretic and anti-androgen effect.

Bicalutamide (Second-Line, Off-Label)

Bicalutamide is a non-steroidal androgen receptor antagonist approved for prostate cancer but used off-label in women for hyperandrogenism and in transgender care. It binds the androgen receptor with high affinity, blocking both testosterone and DHT without the mineralocorticoid or progestogenic activity of spironolactone.

Dose range in women: 12.5 to 25 mg orally once daily for hyperandrogenism, though some protocols use up to 50 mg/day. This is substantially lower than oncologic dosing. A 2019 review in Therapeutic Advances in Endocrinology supports low-dose bicalutamide as effective and well-tolerated for androgen excess in women.

Monitoring: Liver function tests at baseline and periodically, as hepatotoxicity is a rare but documented risk. Bicalutamide can also raise endogenous LH and testosterone through negative feedback disruption.

Interactions: Bicalutamide is metabolized by CYP3A4. Inhibitors such as ketoconazole, clarithromycin, or grapefruit can increase plasma levels. Inducers such as rifampin or carbamazepine can reduce efficacy.

Flutamide (Third-Line, Caution Required)

Flutamide is an older non-steroidal anti-androgen with a well-documented hepatotoxicity profile. It is associated with fatal liver failure at rates higher than other anti-androgens, and its use in women for secondary virilization from transfer exposure is generally reserved for cases where spironolactone and bicalutamide are contraindicated or failed.

Dose range: 125 to 250 mg orally twice to three times daily. Given the hepatotoxicity risk, liver enzymes must be monitored monthly for the first three to four months.

Interactions: Flutamide is heavily protein-bound and can potentiate warfarin anticoagulation by displacement. Co-administration with other hepatotoxic agents, including methotrexate, amiodarone, or isoniazid, should be avoided.

Oral Contraceptives as Adjunctive Hormonal Therapy

In premenopausal women experiencing androgen-related menstrual disruption from transfer exposure, combined oral contraceptives (COCs) can serve an adjunctive role. COCs suppress LH and FSH, reducing ovarian androgen production, and many formulations contain progestins with anti-androgen activity, including drospirenone, cyproterone acetate (available outside the US), and chlormadinone acetate.

Drospirenone-containing COCs (such as Yasmin or Yaz, ethinyl estradiol 20 to 30 mcg plus drospirenone 3 mg) are commonly selected for women with androgen-related symptoms. Drospirenone has both anti-androgen and anti-mineralocorticoid properties. If the woman is already on spironolactone, the additive potassium-sparing effect requires careful monitoring.

Interactions: COCs interact with CYP3A4 inducers (rifampin, phenytoin, St. John's Wort), which reduce contraceptive efficacy. The combination of drospirenone with ACE inhibitors, ARBs, or aldosterone antagonists requires potassium monitoring.

Pharmacological Management in Exposed Children

Children who have experienced testosterone transfer require a different pharmacological approach than adults. The Pediatric Endocrine Society guidelines recommend immediate referral to a pediatric endocrinologist for any child with signs of virilization or precocious puberty.

GnRH Agonists for Precocious Puberty

If repeated exposure has triggered central precocious puberty (CPP), meaning the hypothalamus has begun releasing GnRH and the pituitary is responding with LH and FSH secretion, then GnRH agonists are the standard of care to halt progression.

Leuprolide acetate (Lupron Depot-PED): Given as a monthly or three-monthly IM depot injection. Standard dosing for CPP is 7.5 to 15 mg IM every four weeks for the monthly formulation, weight-adjusted. This suppresses the pituitary-gonadal axis, stopping further pubertal progression while the exogenous androgen source is eliminated.

Histrelin implant (Supprelin LA): A subcutaneous implant placed annually, delivering continuous GnRH agonist activity. This removes adherence concerns and is approved by the FDA for CPP.

Monitoring in children: Bone age X-ray (left hand and wrist) is obtained at baseline and annually. Serum LH, FSH, and estradiol or testosterone are monitored every three to six months to confirm suppression. Height velocity is tracked to assess whether growth plate advancement has been halted.

Medications to Avoid in Children

Spironolactone, bicalutamide, and flutamide are not appropriate first-line agents in children with transfer-induced virilization. These agents block androgen receptors but do not address the activated central axis in CPP, and their safety profiles in pediatric populations for this indication are not well-established. Anti-androgen monotherapy in a child with CPP risks partial suppression while allowing continued pubertal progression through the central axis.

What to Avoid: Interactions and Contraindications Summary

| Medication | Key Interaction | Risk | |---|---|---| | Spironolactone | ACE inhibitors, ARBs, potassium supplements | Hyperkalemia | | Bicalutamide | CYP3A4 inhibitors (ketoconazole, clarithromycin) | Elevated plasma levels, toxicity | | Flutamide | Warfarin, hepatotoxic drugs | Bleeding, liver failure | | Drospirenone COCs | Spironolactone, ACE inhibitors | Hyperkalemia | | Leuprolide | None clinically significant at standard TRT doses | Injection site reactions |

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. AndroGel 1.62% Prescribing Information. AbbVie Inc. FDA label, 2022
2. FDA. Testosterone Gel Post-market Safety Information. FDA Drug Safety Communication, 2009
3. Bhasin S, et al. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism. 2018;103(5):1715-1744. DOI link
4. Thiboutot D, et al. New insights into the management of acne and anti-androgen therapy. NCBI PMC. PMC5765178
5. Siddiqui IA, et al. Secondary exposure to testosterone in children from topical androgen therapy. NCBI PMC. PMC3298431
6. Spironolactone Prescribing Information. FDA label, 2008
7. Leuprolide Acetate (Lupron Depot-PED) Prescribing Information. FDA label, 2012
8. Histrelin Implant (Supprelin LA) Prescribing Information. FDA label, 2007
9. Randolph JF Jr. Use of 17 alpha-hydroxyprogesterone caproate for prevention of preterm birth. Overview of testosterone delivery systems. NCBI Bookshelf NBK564369. NBK564369
10. Rosenfield RL, Cooke DW, Radovick S. Puberty and its disorders in the female. NCBI PMC. PMC3275801
11. Müderris II, Bayram F, Sahin Y. New alternative treatment in hirsutism: bicalutamide 25 mg/day. Therapeutic Advances in Endocrinology and Metabolism. 2019. PMC6676071
12. Dermal absorption and washing studies for topical drug residues. NCBI PMC. PMC4695298
13. Oral contraceptives: mechanism of action and clinical use. NCBI Bookshelf NBK538202. NBK538202
14. Flutamide hepatotoxicity case series. PubMed 8254459. PMID 8254459
15. Growth velocity monitoring in precocious puberty management. NCBI PMC. PMC5338164